StockNews.AI
MRK
StockNews.AI
203 days

Merck Announces Second-Quarter 2025 Dividend and $10 Billion Share Repurchase Authorization

1. Merck declared a quarterly dividend of $0.81 per share. 2. The company authorized an additional $10 billion for treasury stock purchases. 3. Dividends enhance shareholder returns, indicating strong financial health. 4. Treasury stock purchases may support MRK's stock price through reduced share supply. 5. Payment for dividends will occur on April 7, 2025.

Shares Buyback
+0.41%Current Return
VS
-0.31%S&P 500
$97.8801/28 01:45 PM EDTEvent Start
$98.2801/29 08:10 PM EDTLatest Updated
5m saved
Insight
Article

FAQ

Why Bullish?

The dividend increase and share buyback plan signal strong financial performance and shareholder value enhancement, which have historically boosted stock prices, as seen with similar initiatives by other companies in the pharmaceutical sector.

How important is it?

The article discusses significant corporate strategies that directly relate to MRK's financial management and shareholder returns, which are crucial for investor sentiment and stock performance.

Why Short Term?

The immediate effect of the dividend and buyback will likely influence MRK's stock price positively in the near term, similar to previous announcements made by the company.

Related Companies

MRK
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.81 per share of the company’s common stock for the second quarter of 2025. Payment will be made on April 7, 2025, to shareholders of record at the close of business on March 17, 2025. The Board also authorized an additional $10 billion of treasury stock purchases with no time limit for completion. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn. Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2023 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

Related News